<SEC-DOCUMENT>0001628280-17-000232.txt : 20170113
<SEC-HEADER>0001628280-17-000232.hdr.sgml : 20170113
<ACCEPTANCE-DATETIME>20170113170050
ACCESSION NUMBER:		0001628280-17-000232
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170113
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20170113
DATE AS OF CHANGE:		20170113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		17528485

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k-totectagreement.htm
<DESCRIPTION>8-K - TOTECT AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sc26f7e377bd547838e55e0504c18005f"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):                &#160;                        January 13, 2017 (January 9, 2017)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:0%;"></td><td style="width:39%;"></td><td style="width:28%;"></td><td style="width:33%;"></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:  (615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 9, 2017, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing it has entered into an agreement with Clinigen Group plc to acquire exclusive rights to commercialize the FDA approved oncology support drug, Totect</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(dexrazoxane hydrochloride) in the United States. A copy of the press release is furnished as Exhibit 99.1.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:61%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 13, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a8ktotectpressrelease.htm
<DESCRIPTION>EXHIBIT 99.1 TOTACT PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3a01c08e577b42b195593f16cbf12f2e"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;"><img src="cumberland.gif" alt="cumberland.gif" style="font-size:12pt;font-weight:bold;height:97px;width:428px;"><img src="clinigena02.jpg" alt="clinigena02.jpg" style="font-size:12pt;font-weight:bold;height:104px;width:225px;"></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CUMBERLAND PHARMACEUTICALS AND CLINIGEN ENTER EXCLUSIVE </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">U.S. COMMERCIALIZATION AGREEMENT FOR TOTECT</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Nashville, Tenn., January 9, 2017 - Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)</font><font style="font-family:inherit;font-size:12pt;">, a U.S. specialty pharmaceutical company and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinigen Group plc (AIM: CLIN, 'Clinigen')</font><font style="font-family:inherit;font-size:12pt;">, the global pharmaceutical and services company, announce an exclusive agreement to commercialize the oncology support drug, Totect</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(dexrazoxane hydrochloride) in the U.S. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This is the second product Clinigen has licensed to Cumberland under the strategic alliance established in 2015, following the launch of Ethyol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(amifostine) in the U.S. in September 2016.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Totect is an FDA-approved emergency oncology intervention which is indicated to reverse the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body causing severe damage and serious complications. Totect can reverse such damage without the need for additional surgeries and procedures, enabling patients to continue their essential anti-cancer treatment.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under the terms of the agreement, Cumberland has been granted an exclusive U.S. license and will manage all marketing, promotion, and distribution of Totect</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt"> </sup></font><font style="font-family:inherit;font-size:12pt;">in the US. Clinigen will retain responsibility for manufacturing, regulatory and clinical management of the product. Preparations are now underway for the U.S. launch of Totect later this year. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Totect was acquired by Clinigen&#8217;s Specialty Pharmaceuticals (SP) division in 2016 to expand its dexrazoxane portfolio and enter the U.S. market. Clinigen SP will continue to commercialize its existing dexrazoxane products, Savene</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;and Cardioxane</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">, in Europe and other territories outside of the U.S.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;It&#8217;s good to see another product emerge from our strategic partnership with Clinigen, as we continue to selectively expand our line of marketed hospital brands,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;We are keen to help yet another group of oncology patients with Totect, which reflects our mission of delivering products that help improve patients&#8217; quality of care.&#8221;</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Shaun Chilton, Chief Executive Officer of Clinigen Group, added, &#8220;This agreement marks an important milestone for Clinigen. Totect is the second Specialty Pharmaceuticals product that we have exclusively licensed to Cumberland as part of the strategic alliance signed in 2015. Cumberland is a valuable partner, providing us with the opportunity to expand our dexrazoxane portfolio into the sizable U.S. market and enabling patients to access this vital FDA-approved emergency support therapy.&#8221; </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Totect</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(dexrazoxane)</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Totect is an anthracycline extravasation agent approved by the United States Food and Drug Administration. Anthracyclines are used to treat many types of cancer and are among the most common cancer therapies. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Anthracycline extravasation occurs when there is accidental leaking of the intravenously-administered medication into the surrounding tissues.  Anthracycline extravasation can result in serious complications for cancer patients including tissue necrosis with skin ulceration. In addition to tissue damage, an anthracycline extravasation may cause damage to the nerves, tendons, muscle and joints. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Cumberland Pharmaceuticals</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquisition, development, and commercialization of high-quality products that improve the quality of care for patients. The Company has a diverse product portfolio with a focus in the areas of hospital acute care and gastroenterology. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland's marketed products include Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:12pt;">) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:12pt;">) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:12pt;">) Injection, for the treatment of hyponatremia, Omeclamox-Pak</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;for the treatment of </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">H. pylori</font><font style="font-family:inherit;font-size:12pt;">&#32;and duodenal ulcer disease, and Ethyol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(amifostine) for Injection, for the prevention of treatment related adverse reactions in oncology patients.  Cumberland is also dedicated to developing innovative products that address unmet medical needs. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company&#8217;s product candidates in clinical development include: Hepatoren</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Injection for the treatment of hepatorenal syndrome, Boxaban</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Oral Capsule for patients suffering from aspirin exacerbated respiratory disease, VasculanTM </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Oral Capsule for the treatment of systemic sclerosis and Portaban&#8482; </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">(ifetroban</font><font style="font-family:inherit;font-size:12pt;">) Oral Capsule for the treatment of portal hypertension. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information on Cumberland Pharmaceuticals Inc., please visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Clinigen Group </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region). </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information, please visit </font><font style="font-family:inherit;font-size:12pt;color:#0563c1;text-decoration:underline;">www.clinigengroup.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOURCE: Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>clinigena02.jpg
<TEXT>
begin 644 clinigena02.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "< 5,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHID
MTR6\+RRL$CC4LS'H !DF@!9)$AC:21E2-1EF8X 'J36;_P )5HO_ $&-/_\
M I/\:_%C]K+]K7Q1^T1X\U-(M5N[#P/:W#1:7H]O(8XWC4D":4 _.[\M\V0
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MU]#G>'4L#*-*%WILM=_(]/,*=\/)0C=Z&'^R9:[O$GB"YSCR[2./'^\Y.?\
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MYA1117VA[X4444 %%%% !7S#_P %)-573/V1_%:&?R'O+BSM4&?]83<(2O\
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M6BM/#[(9#_ SSQXQ]0K?E7ZNU^:7_!(+1?,USXF:OYG^KM[*T\O'7<TKY_\
M':_2VB6X1V/ ?BG^W)\)O@WXYO\ PCXGU:_M=;L5C:>*'3I95 = ZX91@\$5
MZ)\&_C3X6^/7@X^)_!]U/>:0+F2T\RXMW@;S$QN&UAG'S#FOQT_;FU:;6/VL
M_B/+-()?)ODM4([+'#&H'X<BOTJ_X)OZ6^F_LC^$F> 0FZFO+G(&/,#7#@,?
M7@#\J;CH">MCZ-UV\.GZ'J-T'$1@MI)=Y_AVH3G]*_G5O99M4N+F1F,MS=2N
MQ;N[NQ.?Q)K]_?CUJ\6@_!'Q_J$^?*@T&]9MO7_4./ZU^"7@O2_[8\4>'=-+
M;#=7]K;[O3?*BY_6G$F1_09X%L7TOP1X>LI(_)>VTZWA:/&-I6)01^&*W*;'
M'Y<:H.0H IU9F@5^:/\ P5^U1VU_X8Z:)LQI;7]R8,]"6A4-CW 8?@:_2ZOR
M=_X*S:M#>?M ^&K),^;8^'4\S(X_>7$I&/P%5'<F6QUW_!(/29Y/%GQ,U41
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MXISQA<>1:0Q_7(+?^S5ZC^RI;)'X%U&<##RZ@P8^NU%Q_.OSG"_O<_G+M?\
M*Q\S1][,Y/M?\K'M5?"WQ1NC??$CQ-,PP3?RKQ_LG:/T%?=.0O)K\_?$5T+K
M7=5N=WF+)=32!O4%R<UU<52_<TH=V_R_X)MG,OW<(^9]B_ FU%K\)_#HV;"\
M+2-[EG8Y_&JG[0UTUK\)=8"$ RF*(Y]#(N:Z7X;V;:?\/_#MNY!:.PA!QT^X
M#_6N!_:DNA#\.((=V&FOX@%'? 8G^5>YB/W.5-=H6_ ]&K^[P;\H_H>!_!FU
M^U_%/PVGE^8%NMY&,XVJ3G\,5]NU\=_LXVIN/BQIS X\F":0^_R%?_9J^Q*\
MSAB-L'*7>7Z(Y,G5J#?G_D%%%%?8'N'SI^UM>'S?#5KCY<32Y_[Y&*H?LFVH
M?Q#K]P4RR6L:!O3+DD?H*K?M777F>--(@#Y6.Q)*9Z$N>?QP/RKH_P!DFU==
M.\27)_U;S11CZA23_,5^>1_>\0/R_2)\NO?S3T_R.?\ VJM!^Q^*-+U=%PEY
M;F%V']]#Q^C?I7BS7TTEC%9E\V\4C2HGHS  G\=H_*OK']I;0/[6^&\EXB;I
M=-G2X!_V3\K?H1^5?(]>-G]%T,=)K:6O]?,X,SINGB)-?:U/H3]DFU;S_$MS
MM^3;#$&]_F./Y5]&5X5^R;:^7X9UVYW9\V\5,>FU!_\ %5[K7W^1QY<OI?/\
MSZ;+ERX6']=0HHHKW3T0HHHH **** "ORR_X*XZ7J$?Q<\#:C+$W]ES:+);P
M3;?E\U9BTB9]<,A^E?J;7"_&+X*^$?CQX/D\-^,=,74+ OYL4B-LGMI!P)(G
M'*M^A'!!%-.S$]3\5OV??VF_&W[-.K:G>^$9K1XM3C2.\L=0A,D,I0G8^ 00
MRY8 @]&->X7/_!57XR302)%8>&+=V7 E6RD8J?4 R8S]:^@KG_@D7X"DN)&@
M\<^)(868E(V2W<J.PSLY^M1_\.B? _\ T/OB/_OS;_\ Q-7>+(M(_,G7-:U/
MQ;X@OM5U&>;4]9U.Y:>>9ANDN)I&R3@=26/05^[/[+?@&^^&'[/7@+PQJBE-
M2L-,C%S&W6.1R9&0_P"Z7(_"O-/@/_P3V^&/P-\06WB%5OO%7B&U;?:WFL,I
M2V;L\<2@*&']XY([8KZ=I2=RHJVYXG^VOJTNB_LI?$VZA"ESI#P_-TQ(RQG]
M'-?B%X7UZ7PIXDTC6K>&&YGTV[BO(H;E2T3O&X90P!&1D#O7[T_'CX/VGQX^
M%^K>";[5;S1K/4C%YMU8A3(%217VX8$$': :^2O^'1/@?_H??$?_ 'YM_P#X
MFB+2%)-L\%_X>M?&#_H%>%__  #E_P#CM6](_P""I?QAU76-.L?[-\+1_:[J
M*VW_ &.4[=[JN?\ 6]LU[?\ \.B? _\ T/OB/_OS;_\ Q%:/AO\ X)0>!O#_
M (DTG5CXT\07HT^\AN_LTL4 27RW#[&(7.#C'%/W0]X^XU#*JAR&;') P":_
M'#_@IMJDM_\ M::Q!)C98Z58V\?^Z8S)_.0U^R%?(/QK_P"";WA?XW?%#7?&
M^I^,]>L;W5I(W:UMXX6CB"1K&%4LI.,)G\34Q=F.6J,S_@E!I:6G[.&KWODF
M.6\\1W),A'^L5(H5!'J =P_ U]BZO?1:9I-]>3OY4-O!)*[_ -U54DG\A7 ?
ML\_ W3OV=OAE9^"M*U*ZU:SMKB>X%U>JJR$RR%R"% & 3BN[\0:.GB#0-3TJ
M21H8[ZUEM6D0 L@="I(SW&:3U8UL?SK7TAU":ZD#[S<2.P<]]S$Y_6OZ&OA]
MI<FA^ ?#6FRLK2V>F6MN[+T)2)5)'MQ7Q5:?\$B? MJT&?'?B*1(BI*M#;C<
M 1P?E[XK[PMX5MX(XD&$C4(OT Q52:8HIH^(_P#@K#X!&O?!/0/%<4>ZX\/Z
MJL<C <B"X78<^V]8_P Z_*BWMQ>74%N25$TJ1$CJ-S 9_6OZ!OC!\+]-^,_P
MS\0>"M7EEM[#6+?R'G@ \R(Y#*ZYXR& //I7R/HO_!)GP/H^M:??GQOX@NA:
M7,5QY$D-OMDV.&VMA>AQ@X]:<9)(4DVS[;T'3ET?0].L$8R):VT<"LW4A4"Y
M/Y5\!?\ !7W5EC\+_#72]GS2W]W=>9GH$B1<?CYGZ5^A=?/W[4G['NC_ +4]
MYX>FUKQ+J>BQ:*DRPPZ?'$P=I"NYF+@G.$ J%OJ4]CXF_P""2NDQ7?QR\6W[
M[O-L] VQX/'[R= <_P#?(K]6J^?/V7/V-?#W[+.H>(;W1]=U#7)]8BAA=M0C
MB4Q+&6.%* =2W.?05]!T2U8)61\:_M"074/Q7U9KGI(L3PG'!CV #'X@U6^'
M/QFUOX:V=Q9V4-M>6<S^;Y-P#\KX )!![@#BOJ'XB?"K1?B5;Q#4%D@NX 1#
M>6Y D0'J#G@CV->6M^R3!N.WQ-*%SQFT!/\ Z%7YUBLIS"CC)8C!N]VW>ZOK
MTU/EZV!Q5.O*K0ZG*:Q^U!XGU33I[6&SL=/>52OVB$,SH#P=N3C/O7DMCI\^
MKWUO8VT;37-U(L4:+R69CBOH3_ADB+_H9Y/_  $'_P 57H'P\^!^@?#VZ^W0
MF34=3 PMU<X_=@]=BC@?7K6/]D9ICJL7C'HO-;>21'U'&8F:]N]$=WI-D--T
MNSLU.1;PI"#_ +J@?TKQ']K2\\OP]X?M=N?-NWDW>FU,8_\ 'OTKWBN$^)_P
MGM?BA_9PN]2N;)+/>56!5(8MCDY^GZU]IF6'J8C!SH45J[+\4?08NE*I0E3I
M[L^2O _C6]\ :Y_:VG102W7E-$!<*2H#8R>".>*]"_X:E\6_\^FF?]^F_P#B
MJ[C_ (9,T;_H/ZA_W[C_ ,*/^&2]&_Z#^H?]^T_PKXNAEF=8:'LZ,K+U1\_3
MPF848\M-V7J5OA1\=/$OCSQQ9:/>06$5K(DDDC11L&PJYP#GUQ7O]>6_#_X!
MZ9\/?$::Q;ZG=7LR1/$L<RJ%&[ )X%>HXK[/*Z>*I4+8QWG?O?0][!QK0IVK
MN\CY$_:7N1/\4IXP,&&TA0_D6_K7J7[*EJL7@74;@?>FOV!_X"B@?SK2\<_L
M]Z?XZ\3W>M76LWEO-.%7RHD0JH50 !D5V7P]\#6WP[\-IH]K<274:R/*990
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M#GI7:U\A_LX>-O"G[)O[#O@S7_&5V^G0WD+7Q@1"UQ<S7#M(D<<9/+%-OH
M3P*YJQ_X*K>#$U#33K7@+Q5H6A7SGRM8N(XVC:,''F*H/SJ.,[2<>]%@N?<-
M%5]-U"VU?3[6^LYEN+.ZB6>&9/NNC ,K#V((-6*0PHHHH **** "BBB@ KR7
MXL_ M_B;X@MM335X[ 0VX@\MK?S,X8G.=P]:]:HKEQ.&I8NG[*LKHRJTH5H\
MDU='SA_PR--_T,D/_@&?_BZ/^&1IO^ADA_\  ,__ !=?1]%>5_8.7_\ /O\
M%_YG#_9N%_E_%GSA_P ,C3?]#)#_ . 9_P#BZ/\ AD:;_H9(?_ ,_P#Q=?1]
M%']@Y?\ \^_Q?^8?V;AOY?Q9\X?\,C3?]#)#_P" 9_\ BZ/^&1IO^ADA_P#
M,_\ Q=?1]%+^P<O_ .??XO\ S#^S<-_+^+/G#_AD:;_H9(?_  #/_P 72?\
M#(LW_0RQ?^ 9_P#BZ^D**?\ 8.7_ //O\7_F']FX7^7\6?-__#(LW_0RQ?\
M@&?_ (NC_AD6;_H98O\ P#/_ ,77TA11_867_P#/O\7_ )A_9N%_E_%GS?\
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MKZGHH ****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>cumberland.gif
<TEXT>
begin 644 cumberland.gif
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M.N0GG3[<XBNI?IO?*;G>*7.FMVZ[2K)#"3OK:/%-%8/E)GF=9YY5![(//C0
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M)R.J$RZ:!BN_@A.7I=PUV7G!5[(O(ZY(JV7*/+*E.&)<Z'2B0U-6/LD'UG6
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ME2^9>,>YLYK0/  (_MQN &PB]#LJV-LD#!AXQ2].C2F8) 0]X-P!0D"2+/M
M ]"KH (.,(4Y/[E3J6ASM:O]9C=S8!I0U\<!R! MEP2!'P8X1=;W88!]<-WK
M!A  UT\A]GW3!0("$$ ">J#3#9!= %/J']K3SH/(A*0  @B[ #8@K#&D_>M>
M!WS7 Y_U1@5;*P7 >M?#/OC&@WT?9!\55_ ^=LCO(^^6)_SE3\%WM?0C5 (
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M *<P!H!P@W"7+X82@R@G@>*',"'A=_Q7$L7(%6C3D0^0BA+H!=/A!=+H %0
M!!L@#S"Y0R+Q "-##=FX$HC&3%<(9VYV;>C89J3@?>U("M?V ZE -"#D$:&8
M #18$O(0*@G  PO&A*X'DB6Q 7I'>PPR=U20B!<80#R0=QK0@ !W*LSXBE59
M$@[@>I6(%?48<<T!')0G?R$1E-JQ?TD( "9)D=%E7^I"@@$)D )0B?_"%7;)
M=8E9>+ZX-6/0=7$7;5Q!E*=PF"5!B ; #[37#\='#1MP  6 E.1!*&CA  A@
M#S4B%Y9"4.)PCLK9_Y73\'0_ '7>]V8'\ -30%,R-649Z'HT^(L>P3G/-Q(
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MRZ&WXV[SEVKWGZV7[.2;TWT]>R;QRST/=JXG]*'' )\HB&6=*IM1'2R%"E,
M =2B:VKA7_E9AO(&WM %$EBN%QC2 Y\#!+ZD"PCP^(Y?;KXD?%Q/W%3@2XS/
M^)#_^)D_!L*7V#JM+1I@W;$Q!4#  PB D2%!;H_?^K[T^)B/^9#*GXUJ;K'O
M^IH_^0APNA@HB:=;&H]S'4M9;@B0_Y.2,SV1K_F=KRV;+]A0K"V3?K2M<:SF
M9JE^6FY 8/Q0@C:2" 08^+JVS_FWO_N0FL8M<1I+3B^BG H'H/?*3>I_;QS
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M^#J0P\8Z LI#K?1Z#\.?M&H.1-,HFH^\@7P0![>Y])/@!_XXF";)$:;11Q\
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M'QO'  0!*/%H&.,E/<S'QU^^#B$%2$ "#C C+T23"FD+S10$D !J.$N634S
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EENT,R5'!1LVO-'5DG#8]));2UFF4$%Y62XV/G4S60/F'@   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
